Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TCR-T Cell Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte and Lion TCR Partner To Expand TCR-T Cell Pipeline Globally
Details : Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2024
Lead Product(s) : TCR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : LioCyx-M004
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This designation was granted based on the efficacy of LioCyx-M004, an autologous T-cells transfected with mRNA encoding HBsAg, as demonstrated by an improvement in the overall survival in patients with HBsAg-positive HCC relapsed or refractory to prior s...
Brand Name : LioCyx-M004
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 23, 2021
Lead Product(s) : LioCyx-M004
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?